{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:43:47Z","timestamp":1791211427293,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Reinfections are increasingly becoming a feature in the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, accurately defining reinfection poses methodological challenges. Conventionally, reinfection is defined as a positive test occurring at least 90\u2009days after a previous infection diagnosis. Yet, this extended time window may lead to an underestimation of reinfection occurrences. This study investigated the prospect of adopting an alternative, shorter time window for defining reinfection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A longitudinal study was conducted to assess the incidence of reinfections in the total population of Qatar, from February 28, 2020 to November 20, 2023. The assessment considered a range of time windows for defining reinfection, spanning from 1\u2009day to 180\u2009days. Subgroup analyses comparing first versus repeat reinfections and a sensitivity analysis, focusing exclusively on individuals who underwent frequent testing, were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The relationship between the number of reinfections in the population and the duration of the time window used to define reinfection revealed two distinct dynamical domains. Within the initial 15\u2009days post-infection diagnosis, almost all positive tests for SARS-CoV-2 were attributed to the original infection. However, surpassing the 30-day post-infection threshold, nearly all positive tests were attributed to reinfections. A 40-day time window emerged as a sufficiently conservative definition for reinfection. By setting the time window at 40\u2009days, the estimated number of reinfections in the population increased from 84,565 to 88,384, compared to the 90-day time window. The maximum observed reinfections were 6 and 4 for the 40-day and 90-day time windows, respectively. The 40-day time window was appropriate for defining reinfection, irrespective of whether it was the first, second, third, or fourth occurrence. The sensitivity analysis, confined to high testers exclusively, replicated similar patterns and results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>A 40-day time window is optimal for defining reinfection, providing an informed alternative to the conventional 90-day time window. Reinfections are prevalent, with some individuals experiencing multiple instances since the onset of the pandemic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2024.1363045","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:36:06Z","timestamp":1710117366000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation"],"prefix":"10.3389","volume":"11","author":[{"given":"Hiam","family":"Chemaitelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houssein H.","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi M.","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa A.","family":"Al Thani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad R.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina","family":"Al-Kanaani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einas","family":"Al-Kuwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jeremijenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anvar Hassan","family":"Kaleeckal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Nizar","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyazuddin Mohammad","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan F.","family":"Abdul-Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheyath K.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ghaith","family":"Al-Kuwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel A.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad Eid","family":"Al-Romaihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H.","family":"Al-Thani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullatif","family":"Al-Khal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bertollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith J.","family":"Abu-Raddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"taac109","DOI":"10.1093\/jtm\/taac109","article-title":"Duration of immune protection of SARS-CoV-2 natural infection against reinfection","volume":"29","author":"Chemaitelly","year":"2022","journal-title":"J Travel Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1056\/NEJMc2214114","article-title":"Protection against reinfection with the omicron BA.2.75 subvariant","volume":"388","author":"Chemaitelly","year":"2023","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1056\/NEJMc2200133","article-title":"Protection against the omicron variant from previous SARS-CoV-2 infection","volume":"386","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1038\/s41467-022-32363-4","article-title":"Protection of omicron sub-lineage infection against reinfection with another omicron sub-lineage","volume":"13","author":"Chemaitelly","year":"2022","journal-title":"Nat Commun"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1126\/science.abb5793","article-title":"Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period","volume":"368","author":"Kissler","year":"2020","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1126\/science.abe6522","article-title":"Immunological characteristics govern the transition of COVID-19 to endemicity","volume":"371","author":"Lavine","year":"2021","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature01509","article-title":"Ecological and immunological determinants of influenza evolution","volume":"422","author":"Ferguson","year":"2003","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jmv.1890120103","article-title":"Variation in frequency of natural reinfection with influenza a viruses","volume":"12","author":"Frank","year":"1983","journal-title":"J Med Virol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijid.2022.04.045","article-title":"Epidemiology of influenza virus reinfection in Guangxi, China: a retrospective analysis of a nine-year influenza surveillance data: characteristics of influenza virus reinfection","volume":"120","author":"Wang","year":"2022","journal-title":"Int J Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/cid\/ciz281","article-title":"Influenza a reinfection in sequential human challenge: implications for protective immunity and \"universal\" vaccine development","volume":"70","author":"Memoli","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e1830","DOI":"10.1093\/cid\/ciaa1846","article-title":"Assessment of the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection in an intense reexposure setting","volume":"73","author":"Abu-Raddad","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/cid\/ciab380","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequence characteristics of coronavirus disease 2019 (COVID-19) persistence and reinfection","volume":"74","author":"Choudhary","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"100861","DOI":"10.1016\/j.eclinm.2021.100861","article-title":"SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy","volume":"35","author":"Abu-Raddad","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/01632787211047932","article-title":"A systematic review of the protective effect of prior SARS-CoV-2 infection on repeat infection","volume":"44","author":"Kojima","year":"2021","journal-title":"Eval Health Prof"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"112911","DOI":"10.1016\/j.envres.2022.112911","article-title":"SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity","volume":"209","author":"Pilz","year":"2022","journal-title":"Environ Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMc2001737","article-title":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients","volume":"382","author":"Zou","year":"2020","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"He","year":"2020","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"104684","DOI":"10.1016\/j.meegid.2020.104684","article-title":"Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months","volume":"88","author":"Abu-Raddad","year":"2021","journal-title":"Infect Genet Evol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMsb2104756","article-title":"SARS-CoV-2 variants in patients with immunosuppression","volume":"385","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.chom.2022.01.005","article-title":"SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape","volume":"30","author":"Cele","year":"2022","journal-title":"Cell Host Microbe"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e1003879","DOI":"10.1371\/journal.pmed.1003879","article-title":"Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: a nationally representative cohort study","volume":"18","author":"Abu-Raddad","year":"2021","journal-title":"PLoS Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"23292041","DOI":"10.1101\/2023.06.29.23292041","article-title":"patterns in repeat reinfections: pre and post omicron emergence","volume":"29","author":"Chemaitelly","year":"2023","journal-title":"medRxiv"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1056\/NEJMc2211055","article-title":"Immune imprinting and protection against repeat reinfection with SARS-CoV-2","volume":"387","author":"Chemaitelly","year":"2022","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e13224","DOI":"10.1111\/irv.13224","article-title":"SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: a national cohort study","volume":"17","author":"Mahmoud","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41591-022-01836-w","article-title":"An early warning system for emerging SARS-CoV-2 variants","volume":"28","author":"Subissi","year":"2022","journal-title":"Nat Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of previous infection and vaccination on symptomatic omicron infections","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"taad106","DOI":"10.1093\/jtm\/taad106","article-title":"Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections","volume":"30","author":"Chemaitelly","year":"2023","journal-title":"J Travel Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1473-3099(23)00058-0","article-title":"Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study","volume":"23","author":"Chemaitelly","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMc2117933","article-title":"National Study Group for Covid vaccination. Effectiveness of mRNA-1273 and BNT162b2 vaccines in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1038\/s41598-021-85428-7","article-title":"Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic","volume":"11","author":"Abu-Raddad","year":"2021","journal-title":"Sci Rep"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"ofab221","DOI":"10.1093\/ofid\/ofab221","article-title":"SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar","volume":"8","author":"Al-Thani","year":"2021","journal-title":"Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3201\/eid2705.204365","article-title":"Herd immunity against severe acute respiratory syndrome coronavirus 2 infection in 10 communities","volume":"27","author":"Jeremijenko","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e012291","DOI":"10.1136\/bmjgh-2023-012291","article-title":"All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic","volume":"8","author":"AlNuaimi","year":"2023","journal-title":"BMJ Glob Health"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"05005","DOI":"10.7189\/jogh.11.05005","article-title":"Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19","volume":"11","author":"Ayoub","year":"2021","journal-title":"J Glob Health"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"102646","DOI":"10.1016\/j.isci.2021.102646","article-title":"SARS-CoV-2 seroprevalence in the urban population of Qatar: an analysis of antibody testing on a sample of 112,941 individuals","volume":"24","author":"Coyle","year":"2021","journal-title":"iScience"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1056\/NEJMoa2200797","article-title":"Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijid.2023.09.005","article-title":"Short -and longer-term all-cause mortality among SARS-CoV-2 -infected individuals and the pull-forward phenomenon in Qatar: a national cohort study","volume":"136","author":"Chemaitelly","year":"2023","journal-title":"Int J Infect Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1056\/NEJMc2110300","article-title":"National Study Group for Covid epidemiology. Efficacy of natural immunity against SARS-CoV-2 reinfection with the Beta variant","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41467-022-28199-7","article-title":"Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections","volume":"13","author":"Abu-Raddad","year":"2022","journal-title":"Nat Commun"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"984784","DOI":"10.3389\/fimmu.2022.984784","article-title":"Effects of SARS-CoV-2 alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections","volume":"13","author":"Qassim","year":"2022","journal-title":"Front Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"taac068","DOI":"10.1093\/jtm\/taac068","article-title":"Effects of BA.1\/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections","volume":"29","author":"Qassim","year":"2022","journal-title":"J Travel Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1363045\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:36:09Z","timestamp":1710117369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1363045\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":42,"alternative-id":["10.3389\/fmed.2024.1363045"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1363045","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"article-number":"1363045"}}